FDA Warning Letter to Johnson & Johnson

Johnson & Johnson Consumer Group of Companies, Inc. 9/27/10

Department of Health and Human Services' logoDepartment of Health and Human Services
Public Health Service
Food and Drug Administration
Waterview Corporate Center
10 Waterview Blvd., 3rd Floor
Parsippany, NJ 07054

Telephone (973) 331-4906

http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm227362.htm
U.S. FDA warning letter to Johnson & Johnson

September 27, 2010

WARNING LETTER

HAND DELIVERED

Mark Bowden
Vice President of Global Regulatory Affairs
Johnson and Johnson Consumer Products, Inc.
199 Grandview Road
Skillman, New Jersey 08558-1303

10-NWJ-17

Dear Mr. Bowden:

This letter is in reference to the Listerine Total Care Anticavity Mouthwash distributed by your firm. The label for this product makes the following claims: "Strengthens Teeth, Restores Minerals to Enamel, Fights Unsightly Plaque Above the Gum Line, Helps Prevent Cavities, Kills Bad Breath Germs, and Freshens Breath."

Based on these labeled claims "Fights Unsightly Plaque Above the Gum Line" and "Prevents Cavities," Listerine Total Care Anticavity Mouthwash is a drug as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (Act) (21 U.S.C. § 321(g)) because the product is intended for use in preventing or mitigating disease, or to affect the structure or function of the body, by preventing cavities and removing plaque. Sodium fluoride 0.0221% (0.01% w/v fluoride ion) for the purpose of "Anticavity" is the sole active ingredient listed for this product. This product is subject to the Final sole active ingredient listed for this product. This product is subject to the Final Monograph for Anticaries Drug Products for Over-the-Counter Use, 21 CFR Part 355, which covers the product's disease claim of helping "prevent cavities," and includes this active ingredient.

However, another claim on the label of Listerine Total Care Anticavity Mouthwash is "Fights Unsightly Plaque Above the Gum Line." This statement represents that the product fights plaque, a well-known precursor to gum disease, including gingivitis. Antiplaque/antigingivitis claims are not covered by the Anticaries Final Monograph. Such antiplaque/antigingivitis claims are, however, addressed in the Advanced Notice of Proposed Rulemaking (ANPR) for Oral Healthcare Products for antigingivitis/antiplaque (68 Fed. Reg. 32232 (May 29, 2003)). In that ANPR, the agency identified active ingredients under consideration for inclusion in an antigingivitis/antiplaque monograph; however, sodium fluoride is not among them.

Thus, no mouthwash with sodium fluoride as the active ingredient has been included or proposed for inclusion in any monograph for the antiplaque/antigingivitis indications claimed for Listerine Total Anti-cavity Mouthwash; that ingredient is not included among those under evaluation in the ANPR for antiplaque/antigingivitis drug products, nor does the anticaries monograph at 21 CFR part 355, which does include the active ingredient of sodium fluoride, include antiplaque claims as recognized claims. As formulated and labeled, Listerine Total Anticavity Mouthwash is not generally recognized as safe and effective for the antiplaque indications in its labeling, and it is, therefore, a new drug under section 201(P) of the Act (21 U.S.C. § 321 (P)). Under section 505(a) of the Act (21 U.S.C. § 355(a)), a new drug may not be introduced or delivered for introduction into interstate commerce unless it is the subject of an FDA-approved application. The marketing of Listerine Total Anticavity Mouthwash without an FDA-approved application violates this provision of the Act.

In addition, the front panel of your product states the product name: "Listerine Total Care Anticavity Mouthwash." The violative claims described in the above paragraphs, combined with the appearance of the "Total Care" name, suggests that the product is comprehensive in function, and will provide benefits, including antigingivitis and antiplaque benefits. We are not aware of any support for the antiplaque/antigingivitis claims or other statements suggesting that the product is comprehensive in function, providing benefits beyond those related to prevention of cavities. Thus, the product's labeling claim that it will provide all of the benefits listed, is misleading and accordingly makes it misbranded within the meaning of section 502(a) of the Act. (21 U.S.C. §352(a)).

The violations cited in this letter are not an all-inclusive list of deficiencies. You are responsible for investigating and determining the causes of these violations and for preventing their recurrence and the occurrence of other violations. You are to assure that your firm complies with all requirements of federal law and FDA regulations.

You should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction. Other federal agencies may take this Warning Letter into account when considering the award of contracts.

We note additionally that your principal display panel (PDP) describes your product as "Sodium Fluoride and Acidulated Phosphate Topical Solution." The Drug Facts panel lists the sole active ingredient as "Sodium fluoride 0.0221% (0.01% fluoride ion)." These representations are inconsistent. Based on the information in your Drug Facts panel, it appears that the PDP should refer to either "Sodium Fluoride Acidulated Phosphate Solution" or just "Sodium Fluoride Solution." The Sodium fluoride listed in the drug facts panel should be listed at 0.02%; not 0.0221 %.

Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct the referenced violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your reply should be addressed to Robert J. Maffei, Compliance Officer, at the above address.

Sincerely,

/s/

DIANA AMADOR-TORO
District Director
New Jersey District Office

-
-
Links on this page:

Page Last Updated: 09/28/2010



http://www.goodnewsbroadcast.com/
goodnewsbroadcast web site



National Institute of Health site on bone health and osteoporosis
http://www.niams.nih.gov/Health_Info/Bone/default.asp



Pfizer Consumer Healthcare Issues Voluntary Recall of One Lot of ThermaCare HeatWraps Menstrual Product
http://www.fda.gov/Safety/Recalls/ucm227658.htm

FOR IMMEDIATE RELEASE – September 24, 2010 – Madison, NJ – Pfizer Consumer Healthcare, a business of Pfizer, Inc., announced today a voluntary recall of one lot of its ThermaCare HeatWraps Menstrual product distributed in the United States and Puerto Rico.

The company said it is taking this precautionary step after finding a potential for a leak of the components contained in the wrap, which could cause skin injury such as irritation or burn. The issue is limited to the recalled lot. No other ThermaCare products are impacted. Pfizer has notified the U.S. Food and Drug Administration.

The lot number of the products involved is:
Lot # Exp. Date Product Name
E06831 8/2012 ThermaCare HeatWraps Menstrual



This lot number is listed on both the outer carton and the foil pouch. The lot number may be followed by either an S or an N. For more information on the recall and where to find this information on the package please visit www.thermacare.com9 or call 1-800-323-3383, Monday through Friday, 9am to 5pm est.

Pfizer Consumer HealthCare is removing the product in question from store shelves and asking consumers who have purchased and are still in possession of the affected product to record the lot number, throw the product away in its entirety without opening the foil pouch, and call 1-800-323-3383 for replacement.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

* Online: www.fda.gov/medwatch/report.htm 10
* Regular Mail: use postage-paid FDA form 3500 available at: www.fda.gov/MedWatch/getforms.htm11.
* Mail to MedWatch 5600 Fishers Lane, Rockville, MD 20852-9787
* Fax: 1-800-FDA-0178

Photos: Product Labels12

RSS Feed for FDA Recalls Information13 [what's this?14]
Links on this page:

1. /default.htm
2. /Safety/default.htm
3. /Safety/Recalls/default.htm
4. /Safety/Recalls/default.htm
5. /Safety/Recalls/ArchiveRecalls/default.htm
6. /Safety/Recalls/EnforcementReports/default.htm
7. /Safety/Recalls/IndustryGuidance/default.htm
8. /Safety/Recalls/MajorProductRecalls/default.htm
9. http://www.thermacare.com/
10. http://www.fda.gov/medwatch/report.htm
11. http://www.fda.gov/MedWatch/getforms.htm
12. /Safety/Recalls/ucm227676.htm
13. /AboutFDA/ContactFDA/StayInformed/RSSFeeds/Recalls/rss.xml
14. /AboutFDA/ContactFDA/StayInformed/RSSFeeds/default.htm

Page Last Updated: 09/29/2010


Pertussis (Whooping Cough) – What You Need To Know
http://www.cdc.gov/Features/Pertussis/



Pfizer Consumer Healthcare Issues Voluntary Recall of One Lot of ThermaCare HeatWraps Menstrual Product
http://www.fda.gov/Safety/Recalls/ucm227658.htm

FOR IMMEDIATE RELEASE – September 24, 2010 – Madison, NJ – Pfizer Consumer Healthcare, a business of Pfizer, Inc., announced today a voluntary recall of one lot of its ThermaCare HeatWraps Menstrual product distributed in the United States and Puerto Rico.

The company said it is taking this precautionary step after finding a potential for a leak of the components contained in the wrap, which could cause skin injury such as irritation or burn. The issue is limited to the recalled lot. No other ThermaCare products are impacted. Pfizer has notified the U.S. Food and Drug Administration.

The lot number of the products involved is:
Lot # Exp. Date Product Name
E06831 8/2012 ThermaCare HeatWraps Menstrual



This lot number is listed on both the outer carton and the foil pouch. The lot number may be followed by either an S or an N. For more information on the recall and where to find this information on the package please visit www.thermacare.com9 or call 1-800-323-3383, Monday through Friday, 9am to 5pm est.

Pfizer Consumer HealthCare is removing the product in question from store shelves and asking consumers who have purchased and are still in possession of the affected product to record the lot number, throw the product away in its entirety without opening the foil pouch, and call 1-800-323-3383 for replacement.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

* Online: www.fda.gov/medwatch/report.htm 10
* Regular Mail: use postage-paid FDA form 3500 available at: www.fda.gov/MedWatch/getforms.htm11.
* Mail to MedWatch 5600 Fishers Lane, Rockville, MD 20852-9787
* Fax: 1-800-FDA-0178



RSS Feed for FDA Recalls Information13 [what's this?14]
Links on this page:

1. /default.htm
2. /Safety/default.htm
3. /Safety/Recalls/default.htm
4. /Safety/Recalls/default.htm
5. /Safety/Recalls/ArchiveRecalls/default.htm
6. /Safety/Recalls/EnforcementReports/default.htm
7. /Safety/Recalls/IndustryGuidance/default.htm
8. /Safety/Recalls/MajorProductRecalls/default.htm
9. http://www.thermacare.com/
10. http://www.fda.gov/medwatch/report.htm
11. http://www.fda.gov/MedWatch/getforms.htm
12. /Safety/Recalls/ucm227676.htm
13. /AboutFDA/ContactFDA/StayInformed/RSSFeeds/Recalls/rss.xml
14. /AboutFDA/ContactFDA/StayInformed/RSSFeeds/default.htm

Page Last Updated: 09/29/2010


Wonderful World MSNBC web site
http://www.msnbc.msn.com/id/13282721/

http://www.articlesbase.com/
articlesbase web site



FDA Orders Halt to Marketing of Unapproved Single-Ingredient Oral Colchicine
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm227796.htm
Thu, 30 Sep 2010 13:00:00 -0500



http://www.findhow.com



Fisher-Price Recalls
http://www.cpsc.gov/cpscpub/prerel/prerelsep10.html
Fisher-Price Recalls Infant Toys with Inflatable Balls Due to Choking Hazard

In cooperation with the U.S. Consumer Product Safety Commission and Health Canada, Fisher-Price Inc., of East Aurora, N.Y., is voluntarily recalling about 2.8 million Baby Playzone™ Crawl & Cruise Playgrounds™, Baby Playzone™ Crawl & Slide Arcades™ , Baby Gymtastics™ Play Wall, Ocean Wonders™ Kick & Crawl™ Aquarium (C3068 and H8094), 1-2-3 Tetherballs™, and Bat & Score Goals™ (in the United States and 125,000 in Canada). The valve of the inflatable ball on these toys can come off and pose a choking hazard to young children.

Fisher-Price Recalls Healthy Care, Easy Clean and Close to Me High Chairs Due to Laceration Hazard

In cooperation with the U.S. Consumer Product Safety Commission and Health Canada, Fisher-Price Inc., of East Aurora, N.Y., is voluntarily recalling about 950,000 Healthy Care, Easy Clean and Close to Me High Chairs (in the United States and 125,000 in Canada). Children can fall on or against the pegs on the rear legs of the high chair resulting in injuries or lacerations. The pegs are used for high chair tray storage.

Fisher-Price Recalls Little People Wheelies Stand 'n Play Rampway Due to Choking Hazard

In cooperation with the U.S. Consumer Product Safety Commission and Health Canada, Fisher-Price Inc., of East Aurora, N.Y., is voluntarily recalling about 100,000 Fisher-Price Little People Wheelies Stand 'n Play Rampways (in the United States and 20,000 in Canada). The wheels on the purple and the green cars can come off, posing a choking hazard to young children.

Fisher-Price Recalls Children's Trikes Due to Risk of Serious Injury

In cooperation with the U.S. Consumer Product Safety Commission and Health Canada, Fisher-Price Inc., of East Aurora, N.Y., is voluntarily recalling about 7 Million Fisher Price Trikes and Tough Trikes toddler tricycles (in the United States and 150,000 in Canada). A child can strike, sit or fall on the protruding plastic ignition key resulting in serious injury, including genital bleeding



http://www.lightningsafety.noaa.gov/
National Weather Service
Check this site for handouts, indoor safety and outdoor risk reduction tips, medical facts, history, survivor stories, photos, teacher tools, kids page and more.


Sepsis
http://www.nlm.nih.gov/medlineplus/sepsis.html



http://www.smartertravel.com/
smartertravel web site



U,S. FDA Enforcement Report for September 29, 2010
http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm227948.htm
RECALLS AND FIELD CORRECTIONS: FOODS - CLASS I



FDA Orders Most Colchicine Products Off the Market
http://www.medpagetoday.com/PublicHealthPolicy/FDAGeneral/22506



Brain Basics: Know Your Brain
http://www.ninds.nih.gov/disorders/brain_basics/know_your_brain.htm


flu gov web site
http://www.flu.gov/



foodtimeline web site
http://www.foodtimeline.org/index.html


ready gov web site
http://www.ready.gov/



Sprouts: What You Should Know
http://www.foodsafety.gov/keep/types/fruits/sprouts.htmlDo sprouts carry a risk of illness? Like any fresh produce that is consumed raw or lightly cooked, sprouts carry a risk of foodborne illness. Unlike other fresh produce, seeds and beans need warm and humid conditions to sprout and grow. These conditions are also ideal for the growth of bacteria, including Salmonella, Listeria, and E. coli.




On September 30, 2010, while I was at Pancake House, Inc. at Level 4, Robinsons Place, Ermita, Manila, I didn't see required express lane for senior citizens in the customer area of said restaurant. I also didn't see, in the customer area of said restaurant, sign, etc. regarding privileges of senior citizens. Front line employee at said restaurant didn't have health certificate attached in the proper position on the clothing she was wearing. Proof of purchase is said restaurant's official receipt No. 1761 dated Sept. 30, 2010.


Bureau of Foods and Drugs ignored referral letter from DTI?

Based on evidence, a " Asst. Sec, Ma.Theresa "Angel" Pelayo National Capital Region Regional Operations Group" wrote a referral letter addressed to DIR Leticia
Barbara B. Gutierrez, of said bureau and dated December 23, 2008. Said letter contained the following words: ". . . referred . . . the herein attached two (2)
advisories from . . . M. Silva . . . relative to personal care creams, as the subject items/products fall within the jurisdiction that office. Action on the above
subject may be directly communicated to the complainant . . ." Up to October 3, 2010, said Bureau has not communicated with me regarding said advisories.


customer advisory vs. Star Appliance Center, Inc.
which was at SM Appliance Center, SM Makati Annex Bldg., Ayala Center, Makati.
On April 08, 2010, said firm required me to pay in advance, Philippine pesos 500, for installation by Ramecon Industries Corporation, of a room type air conditioner.
Proof of said payment is a copy of SM Appliance Center sales invoice with the above date and numbered 12251. The installation by said Ramecon Industries was not done
properly. For approximately 14 days after said installation, every time I turned on said air conditioner, excessive sound emanated from the vicinity of said air conditioner. The address of said Ramecon Industries Corporation was: 2300 Aurora Blvd., Pasay City.



St. Luke's Medical Center ignored DTI?
I have a letter dated June 2, 2009 identified as from the Department of Trade and Industry addressed to St. Luke's Medical Center in Quezon City. Said letter contains the words: "
. . . we refer to you the attached self-explanatory letter of concern from . . . M. Silva of 757 J.P. Rizal St., Makati City regarding various services and facilities
available/offered by your establishment. Information and assistance with the action taken thereon may be directly coordinated to Mr. Silva." Up to October 2, 2010,
Said establishment has not communicated with me regarding said letter.